EDITORIAL SYNOPSIS It has been suggested that there may be subclinical deficiency of pyridoxine in patients with tropical and non-tropical sprue. This paper provides evidence of some failure of absorption of pyridoxine in idiopathic steatorrhoea.
Impaired absorption of certain water-soluble vitamins may be caused by disease of the small intestine. Patients with idiopathic steatorrhoea, for instance, almost invariably fail to absorb folic acid normally (Girdwood, 1953; Chanarin, Anderson, and Mollin, 1958; Cox, Meynell, Cooke, and Gaddie, 1958) , and also suffer from folic acid deficiency. Clinical evidence of deficiency of other water-soluble vitamins, however. is rarely apparent and Girdwood (1956 ) was unable to demonstrate malabsorption of aneurine, riboflavine, or pyridoxine in 10 patients with impaired absorption of folic acid. Recently subclinical deficiency of pyridoxine in patients with tropical or non-tropical sprue has been suggested by reports that there is an increase in the urinary excretion of xanthurenic acid and other metabolites of 1-tryptophan after an oral dose of this amino-acid (Kowlessar, Haeffner, Benson, and Sleisenger, 1961; Sigler, Sheehy, Santini, and Rubini, 1962) and Baker and Sobotka (1962) have now shown that patients with nontropical sprue may have subnormal levels of pyridoxine in their serum. These observations suggest that there may be a failure of absorption of pyridoxine in idiopathic steatorrhoea.
The successful labelling of pyridoxine with tritium has made it possible to study the absorption of the labelled vitamin directly Brain, Stewart, and Booth, 1963) and its use overcomes the limitations of the microbiological method employed by Girdwood (1956) . This paper reports a study of the absorption of 3H-labelled pyridoxine in control subjects and in patients with a variety of conditions associated with intestinal malabsorption. ' studied by measuring the urinary radioactivity during the 24 hours following the test dose. The radioactive test doses were given to the subjects after an overnight fast, either alone or immediately after a parenteral injection of non-radioactive pyridoxine hydrochloride, a procedure which was found greatly to increase the urinary excretion of radioactivity. The urine passed during the 24 hours following the oral dose of labelled pyridoxine was usually collected in the following periods: 0 to 3 hours, 3 to 6 hours, 6 to 12 hours, and 12 to 24 hours. In some instances urine was collected at shorter intervals. The volume of each collection was measured and an aliquot was stored at -20°C. until the radioactivity was measured.
ASSAY OF URINE SAMPLES Radioactivity of the urine samples was assayed in a Packard Tri-Carb liquid scintillation counter, using 2-5,diphenyloxazole and 1,4-bis (2,5-diphenyloxazolyl) benzene with naphthalene, dissolved in a mixture of toluene, dioxane, and ethanol as the liquid scintillator. Volumes, each of 0-5 ml, of the urine to be counted were added to 10 ml. of the liquid 241 scintillator and 0 05 ml. of the test dose was added as an internal standard to all samples.
SUBJECTS STUDIED
CONTROLS Control subjects were ambulant hospital patients in whom there were no clinical grounds for suspecting malabsorption.
PATIENTS Patients with intestinal malabsorption included 16 patients in whom the diagnosis of idiopathic steatorrhoea had been confirmed by jejunal biopsy (Table IV) , and nine patients with steatorrhoea due to other causes. Four of these latter patients had had extensive resections of the distal small intestine and two others had Crohn's disease involving the ileum; there was also one patient with a duodeno-colic fistula, one who had steatorrhoea associated with a subtotal gastrectomy, and one with chronic pancreatitis. ranged from 8-8 to 19-2 (mean 11-9%). In five of these subjects the test was repeated 48 hours after 300 mg. non-radioactive pyridoxine hydrochloride had been given intravenously. Under these circumstances, the amount excreted ranged from 13-3 to 21-5% of the oral dose (Table I) . Although the differences in excretion were variable in different patients, the mean percentage excretion after 'saturation' with pyridoxine (16-8 %) was slightly greater than when no previous pyridoxine had been given and this difference is significant (t -± 3-24 P = <0-01 CONTROLS The percentage excretion in nine subjects given 1-0 mg. 3H-pyridoxine orally and 100 mg. non-radioactive pyridoxine intravenously who had previously received no pyridoxine, and in 14 subjects who had received 300 mg. pyridoxine 48 hours before the test, is given in Table II . Although the mean excretion after 'saturation' rose from 440% to 50 5 %, this difference is not significant (t -± 162 0-2>P>0-1).
RESULTS

URINARY EXCRETION OF
Four 'saturated' subjects were also given the 10 mg. test dose of 3H-pyridoxine intramuscularly and a simultaneous injection of 100 mg. nonradioactive pyridoxine was given intravenously. The urinary excretion of radioactivity during the ensuing 24 hours ranged from 33-8 to 68 7% (mean 51-0%, S.E. ± = 7 8). These results are similar to those recorded when the same dose was given by mouth (Table II) . Table I ). For convenience, these results have been plotted on double logarithmic paper. There was a direct linear relationship between the amount of 3H-pyridoxine given orally and the amount excreted in the urine.
RATE OF URINARY EXCRETION OF RADIOACTIVITY
IDIOPATHIC STEATORRHOEA The urinary excretion of radioactivity was measured in these cases under different conditions.
Urinary excretion of radioactivity afier 1-0 mg.
3H-pyridoxine orally In 16 patients with idiopathic steatorrhoea the urinary excretion of radioactivity was measured after 1-0 mg. 3H-pyridoxine was given orally, together with a 100 mg. 'flushing' injection. In 13 of these patients, the test was repeated after previous saturation with 300 mg. of non-radioactive pyridoxine given intravenously. The results are given in Table III. Before saturation, the percentage urinary excretion of radioactivity ranged from 190 to 5000%
(mean 29-95 %). After saturation, the excretion was slightly greater, between 20 0 and 57 0% (mean 36 75 %), but this difference is not significant (t = ± 1 79, 0O1>P>005). If these results are compared with those obtained in control subjects (Table II) it is seen that six of the patients excreted less radioactivity than any of the control subjects, whereas in the other seven patients 'Saturation was achieved as before (see Table I ). excretion was within the control range. The mean excretion after saturation in patients with idiopathic steatorrhoea shows a highly significant difference from the mean in saturated control subjects (Table  II) (t = ± 3-38, P<0-01). Rate of urinary excretion of radioactivity after 1-0 mg. 3H-pyridoxine orally In Fig. 4 the cumulative urinary excretion of radioactivity in a patient with idiopathic steatorrhoea given an oral dose of 1.0 mg. of 3H-pyridoxine, together with a flushing injection of 200 mg. of non-radioactive pyridoxine, is shown together with the results obtained in the control subject studied similarly (Fig. 2) . In the patient with idiopathic steatorrhoea the total excretion in 12 hours was half that of the control subject, and the rate of excretion was consistently less. Nevertheless, the period of maximum excretion occurred at approximately the same time as in the control subject. Urinary excretion of radioactivity after increasing oral doses of 3H-pyridoxine One of the patients (case 11, Table IV), whose urinary excretion of radioactivity from the standard oral test dose was within the normal range, was given further oral test doses of 10 mg. and 100 mg. 3H-pyridoxine together with a 200 mg. flushing injection. The urinary excretion of radioactivity has been calculated as milligrams pyridoxine and is plotted in Figure 5 . The results at all three dose levels lie within the normal range and do not differ significantly from the regression equation calculated from the controls (Fig. 3 ) (0 95>P>0-90).
Correlation of pyridoxine absorption uith other parameters of intestinal function and histological appearance of the jejunal mucosa In Table IV , the percentage of the oral dose of 10 mg. of 3H-pyridoxine excreted in the urine by 13 patients with idiopathic steatorrhoea studied after previous saturation is compared with the results of folic acid absorption, xylose excretion, faecal fat excretion, and the histological appearance of the jejunal mucosa. These results indicate that there was no correlation between pyridoxine absorption and any other parameter of intestinal function. For example, although the patients whose absorption of folic acid and fat was normal (cases 7 and 10) absorbed pyridoxine normally, another patient who had gross steatorrhoea (case 11) and total failure of folic acid absorption also excreted normal amounts of 3H-pyridoxine. There was no clear difference in the result of pyridoxine absorption between those with 'partial' or 'subtotal' villous atrophy (Table IV) .
INTESTINAL RESECTION Urinary excretion of radioactivity was studied in a small number of patients who had had varying amounts of small intestine resected.
Urinary excretion of radioactivity from an oral dose of 10 mg. 3H-pyridoxine Four patients who had undergone extensive resection of varying amounts of the distal small intestine were given the standard oral test dose of 1.0 mg. 3H-pyridoxine together with 100 mg. non-radioactive pyridoxine intravenously, all patients having been previously saturated with 300 mg. pyridoxine intravenously 48 hours before the test. One patient (case 17) received a further oral dose of 20 mg. 3H-pyridoxine with a 200 mg. flushing injection. The urinary excretion of radioactivity, together with the estimated length of small intestine remaining, is given in Table V. One patient (case 17) had only 4 feet of proximal small intestine remaining but excreted normal amounts of radioactivity after an oral dose of either 1-0 or 20 0 mg. The other three patients (cases 14, The results of the test were normal patients (Table VI) . The results reported in this paper 3H-pyridoxine may be used to study of this vitamin in man. When radioact is given orally relatively little ra excreted in the urine during the follov If, however, the oral dose is accor relatively large parenteral injection active pyridoxine, much larger amoi activity are excreted (Fig. 1) . This analogous to the Schilling test of absorption and has been successfully study of absorption of 3H-pyridoxii . The observ non-radioactive pyridoxine promoter excretion of the labelled vitamin fur that as in the rat the 3H-labelled pyrid similarly to the unlabelled material tritium label is not detached during pa the body. eet of jejunum
In control subjects 3H-pyridoxine was absorbed the percentage relatively rapidly, for the rate of urinary excretion normal range; following an oral dose suggested that the major vas reduced to period of absorption was the first two hours after feeding (Fig. 2) (Brain, 34.4 40-0 Stewart, and Booth, 1963 (Turner and Hughes, 1962; Wilson, 1962) and the linear relationship between oral dose and urinary excretion of 3H-pyridoxine demonstrated in this indicate that paper (Fig. 3) is compatible with a diffusion mechthe absorption anism for the absorption of pyridoxine in man. tive pyridoxine Although only 50% of the dose was excreted in the .dioactivity is urine in these experiments, it is likely that most if wing 24 hours. not all of the oral 3H-pyridoxine was absorbed, for mpanied by a a similar percentage was excreted when the labelled of non-radio-vitamin was given parenterally. Failure to excrete unts of radio-more of the administered radioactivity must reflect technique is some alternative metabolic pathway than urinary vitamin B12 excretion. A similar situation has been recorded in applied to the studies of the metabolism of 3H-pyridoxine in the ne in the rat rat (Cox, Murray, and Boone, 1962) .
ation that the In six out of 13 patients with idiopathic steators the urinary rhoea there was evidence of impaired absorption of rther indicates pyridoxine, for they excreted less radioactivity in loxine behaves the urine than any of the control subjects ( Table III with marked malabsorption (cases 1, 2, 3, and 4, for instance) failed to absorb pyridoxine normally, and there were two patients (cases 7 and 10) whose normal absorption of folic acid and fat was associated with a normal excretion of 3H-pyridoxine. However, there were other patients who absorbed pyridoxine normally even when there was marked malabsorption of substances such as folic acid or fat (cases 9 and 11). The most striking example of this discrepancy was the patient (case 11) whose absorption of folic acid, xylose, and fat was grossly impaired yet who absorbed pyridoxine normally from oral doses of 1, 10, or 100 mg. (Fig. 5) . This patient's jejunal biopsy showed an extreme degree of mucosal atrophy. There was also no correlation between the capacity of these patients to absorb pyridoxine and the severity of the changes in the jejunal biopsy. The results in idiopathic steatorrhoea demonstrate the variability of absorption of different substances in different patients and provide a rational explanation for the very variable nutritional deficiences which may occur in this condition. Malabsorption of pyridoxine in these patients also explains why abnormalities of tryptophan metabolism (Kowlessar et al., 1961; Sigler et al., 1962) and subnormal serum pyridoxine levels (Baker and Sobotka, 1962) may occur in idiopathic steatorrhoea.
